Dermatologia
Permanent URI for this community
Browse
Browsing Dermatologia by Subject "Anti-Inflamatórios Não Esteróides"
Now showing 1 - 4 of 4
Results Per Page
Sort Options
- A European multicentre photopatch test studyPublication . Gonçalo, Margarida; European Multicentre Photopatch Test Study (EMCPPTS) TaskforceBACKGROUND: The two most common agent groups currently responsible for photoallergic contact dermatitis (PACD) are organic ultraviolet (UV) absorbers in sunscreens and topical nonsteroidal anti-inflammatory drugs (NSAIDs). However, availability of information on the photoallergenic potential of these agents is scarce. OBJECTIVES: To obtain current information on the frequency of PACD to 19 organic UV absorbers and five topical NSAIDs, including newer agents, in common usage in Europe. METHODS: A prospective, multicentre photopatch test study was conducted with 1031 patients attending for investigation of suspected PACD in 30 centres across 12 European countries. RESULTS: A total of 346 PACD reactions in 200 (19·4%) subjects occurred. PACD was most commonly caused by the topical NSAIDs, ketoprofen (128 subjects) and etofenamate (59 subjects). Of the organic UV absorbers, octocrylene, benzophenone-3 and butyl methoxydibenzoylmethane most frequently elicited PACD. The 'newer' organic sunscreen absorbers rarely led to PACD. There appeared to be an association between the agents ketoprofen, octocrylene and benzophenone-3, with several subjects developing PACD to two or all three agents concomitantly. Allergic contact dermatitis (ACD) was less commonly observed than PACD, comprising 55 reactions in 47 (5%) subjects. Irritant reactions and photoaugmentation and photoinhibition of ACD occurred infrequently. CONCLUSIONS: The European multicentre photopatch test study has provided current information on the relative frequency of PACD to common photoallergens. Such data will be of value when deciding on which agents to include in a future European 'baseline' photopatch test series.
- Photoallergic contact dermatitis from benzydamine presenting mainly as lip dermatitisPublication . Canelas, MM; Cardoso, JC; Gonçalo, Margarida; Figueiredo, ABACKGROUND: Benzydamine, a non-steroidal anti-inflammatory drug (NSAID) in use for more than four decades, has been reported to cause photosensitivity. OBJECTIVES: To study the results of photopatch testing to benzydamine and the clinical features of the dermatitis during a 3-year period (2006-2008). PATIENTS AND METHODS: During this period, 74 patients with photodermatoses were photopatch tested with an extended baseline series of allergens including benzydamine and in suspicious cases, with drugs that contain it. Test sites were irradiated on D2 with 5 J/cm(2) and readings were performed on D2 and D4. RESULTS: Ten patients (six females/four males), aged 21-84 years (mean 64.9) had a positive photopatch test to benzydamine [1-5% petrolatum (pet.) from Bial-Aristegui] and to drugs that contain it (Tantum verde oral solution and Momen gel). Nine patients had lower lip cheilitis and one lichenified eczema on photo-exposed sites. CONCLUSION: Photosensitivity from both topical and systemic benzydamine has been occasionally described, mainly in southern Spain. Despite its widespread use and its known photosensitizing capacity, photoallergic contact dermatitis from benzydamine is probably underdiagnosed as the clinical presentation of mainly the lip and chin is not typical of photoallergic contact dermatitis and benzydamine is not part of most photoallergen series.
- Photopatch testing with an extended series of photoallergens: a 5-year studyPublication . Cardoso, JC; Canelas, MM; Gonçalo, Margarida; Figueiredo, AOBJECTIVE: We conducted a retrospective study (2003-07) evaluating the results of photopatch tests (PPTs) performed with an extended series with the objective of determining the main photoallergens in our region and whether they would be detected by a recently recommended baseline PPT series. MATERIALS AND METHODS: 83 patients (58 females/25 males, mean age 54.8 years) were tested with a photoallergen series, and among these, 30 were also tested with a non-steroidal anti-inflammatory drug (NSAID) series, irradiated at D2 with 5 J/cm(2) ultraviolet A (UVA). RESULTS: Thirty-six of 83 patients (43.3%) had at least one positive reaction, with 21 (25.3%) reacting in the photoallergen series. The main relevant reactions were as follows: 10 to ultraviolet filters (benzophenone-3 and benzophenone-4, 3 patients each), 7 to promethazine, and 2 to chlorpromazine. Twenty of 30 patients tested (70%) had a relevant positive PPT to an NSAID, 9 to piroxicam because of systemic photosensitivity, 8 to benzydamine from a topical gel or oral solution, and 2 to ketoprofen. CONCLUSIONS: Our results are discordant with most recently published studies because of the particularities of the population studied and to regional prescribing habits. Therefore, apart from the recommended baseline series of photoallergens, other substances must be tested according to regional peculiarities.
- Topical provocation in fixed drug eruption from nonsteroidal anti-inflammatry drugsPublication . Gonçalo, Margarida; Oliveira, HS; Fernandes, B; Robalo-Cordeiro, M; Figueiredo, A